• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Evidence Table 9Evidence profile of hypertension trials: Valsartan compared with lisinopril

Quality AssessmentSummary of Findings
StudyDesignQualityInconsistencyIndirectnessImprecisionOther considerationsResults by study, Relative effectQuality of the evidence for each outcome
Mortality
Menne 2008 n=133RCTFairConsistentDirectImpreciseNone1 death (2%) occurred in the lisinopril groupModerate
Malacco 2004 n=1213RCTGoodNo deaths occurred in either group
Overall withdrawals
Menne 2008 n=133RCTFairConsistentDirectPreciseNoneNSD between groupsHigh
Malacco 2004 n=1213RCTGoodNSD between groups
Cough
Menne 2008 n=133RCTFairInconsistentDirectPreciseNoneNSD between groupsLow
Malacco 2004 n=1213RCTGoodSignificantly higher incidence in lisinopril group
Overall adverse events
Menne 2008 n=133RCTFairInconsistentDirectPreciseNoneNSD between groupsLow
Malacco 2004 n=1213RCTGoodSignificantly higher incidence in lisinopril group
Withdrawals due to adverse events
Menne 2008 n=133RCTFairInconsistentDirectImpreciseNoneNSD between groupsLow
Malacco 2004 n=1213RCTGoodSignificantly higher incidence in lisinopril group

From: Evidence Tables

Cover of Drug Class Review: Direct Renin Inhibitors, Angiotensin Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers
Drug Class Review: Direct Renin Inhibitors, Angiotensin Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers: Final Report [Internet].
Norris S, Weinstein J, Peterson K, et al.
Portland (OR): Oregon Health & Science University; 2010 Jan.
Copyright © 2009, Oregon Health & Science University, Portland, Oregon.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.